CL2019000729A1 - Proteínas de unión recombinantes y sus usos. - Google Patents
Proteínas de unión recombinantes y sus usos.Info
- Publication number
- CL2019000729A1 CL2019000729A1 CL2019000729A CL2019000729A CL2019000729A1 CL 2019000729 A1 CL2019000729 A1 CL 2019000729A1 CL 2019000729 A CL2019000729 A CL 2019000729A CL 2019000729 A CL2019000729 A CL 2019000729A CL 2019000729 A1 CL2019000729 A1 CL 2019000729A1
- Authority
- CL
- Chile
- Prior art keywords
- union
- recombinating
- associdus
- proteins
- binding proteins
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 230000034994 death Effects 0.000 abstract 1
- 231100000517 death Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE DESVELAN NUEVAS PROTEÍNAS DE UNIÓN RECOMBINANTES, QUE COMPRENDEN DOMINIOS DISEÑADOS CON REPETICIONES DE ANQUIRINA CON ESPECIFICIDAD DE UNIÓN PARA EL HER2, Y QUE COMPRENDEN DOMINIOS DISEÑADOS CON REPETICIONES DE ANQUIRINA CON ESPECIFICIDAD DE UNIÓN PARA LA SEROALBÚMINA, ASÍ COMO LOS ÁCIDOS NUCLEICOS QUE CODIFICAN DICHAS PROTEÍNAS DE UNIÓN RECOMBINANTES, COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN DICHAS PROTEÍNAS DE UNIÓN RECOMBINANTES O ÁCIDOS NUCLEICOS Y EL USO DE DICHAS PROTEÍNAS DE UNIÓN RECOMBINANTES, ÁCIDOS NUCLEICOS O COMPOSICIONES FARMACÉUTICAS EN EL TRATAMIENTO DE ENFERMEDADES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16190221 | 2016-09-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019000729A1 true CL2019000729A1 (es) | 2019-06-14 |
Family
ID=57046984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019000729A CL2019000729A1 (es) | 2016-09-22 | 2019-03-21 | Proteínas de unión recombinantes y sus usos. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10717772B2 (es) |
| EP (1) | EP3515933B9 (es) |
| JP (1) | JP6976335B2 (es) |
| KR (1) | KR102270315B1 (es) |
| CN (1) | CN109790206A (es) |
| AR (1) | AR109680A1 (es) |
| AU (1) | AU2017331329B2 (es) |
| BR (1) | BR112019005587A2 (es) |
| CA (1) | CA3036301C (es) |
| CL (1) | CL2019000729A1 (es) |
| CO (1) | CO2019002609A2 (es) |
| ES (1) | ES2953516T3 (es) |
| IL (1) | IL265489B (es) |
| MX (1) | MX377424B (es) |
| MY (1) | MY196882A (es) |
| NZ (1) | NZ751689A (es) |
| PH (1) | PH12019500596B1 (es) |
| SA (1) | SA519401369B1 (es) |
| WO (1) | WO2018054971A1 (es) |
| ZA (1) | ZA201901592B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021014649A (es) | 2019-06-04 | 2022-01-06 | Molecular Partners Ag | Dominio de repetición de anquirina diseñado con estabilidad mejorada. |
| EP3980045A1 (en) * | 2019-06-04 | 2022-04-13 | Molecular Partners AG | Recombinant fap binding proteins and their use |
| CA3139051A1 (en) * | 2019-06-04 | 2020-12-10 | Christian REICHEN | Multispecific proteins |
| JP2022535107A (ja) * | 2019-06-04 | 2022-08-04 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 組換え４－１ｂｂ結合タンパク質及びそれらの使用 |
| CN115003689A (zh) | 2019-12-11 | 2022-09-02 | 分子合作伙伴股份公司 | 具有改变的表面残基的经设计的锚蛋白重复结构域 |
| MX2022013945A (es) | 2020-05-06 | 2023-02-14 | Molecular Partners Ag | Nuevas proteinas de union a repeticiones de anquirina y sus usos. |
| BR112022023049A2 (pt) | 2020-05-14 | 2022-12-20 | Molecular Partners Ag | Proteínas multiespecíficas |
| JP2023528207A (ja) * | 2020-05-14 | 2023-07-04 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 組換えｃｄ４０結合タンパク質及びそれらの使用 |
| CA3202358A1 (en) | 2020-12-16 | 2022-06-23 | Andreas BOSSHART | Novel slow-release prodrugs |
| WO2022190008A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Protease cleavable prodrugs |
| CA3211248A1 (en) | 2021-03-09 | 2022-09-15 | Nina RESCHKE | Novel darpin based cd33 engagers |
| CA3211368A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based cd123 engagers |
| EP4304731A1 (en) | 2021-03-09 | 2024-01-17 | Molecular Partners AG | Novel darpin based multi-specific t-cell engagers |
| AU2022413461A1 (en) | 2021-12-14 | 2024-06-06 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
| IL318514A (en) | 2022-08-01 | 2025-03-01 | Molecular Partners Ag | Loading and using modified re-designed websites |
| WO2024038307A1 (en) | 2022-08-19 | 2024-02-22 | Novartis Ag | Dosing regimens for sars-cov-2 binding molecules |
| TW202448926A (zh) | 2023-02-17 | 2024-12-16 | 比利時商艾伯霖克斯公司 | 結合新生兒fc受體之多肽 |
| WO2024179981A1 (en) | 2023-02-27 | 2024-09-06 | Molecular Partners Ag | Darpins for use in reducing renal accumulation of drugs |
| WO2024251628A1 (en) | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd16a binding proteins and their use |
| WO2024251742A1 (en) | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd2 binding proteins and their use |
| WO2025146487A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Multispecific binding proteins |
| WO2025146491A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent |
| WO2025163144A1 (en) | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Recombinant mesothelin binding proteins and their use |
| WO2025181039A1 (en) | 2024-03-01 | 2025-09-04 | Molecular Partners Ag | Therapeutic combinations comprising a multi-specific t cell engager |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| DK1567641T3 (da) * | 2001-08-24 | 2012-08-27 | Uvic Industry Partnerships Inc | Proaerolysin indeholdende proteaseaktiveringssekvenser og fremgangsmåder til anvendelse til behandling af prostatacancer. |
| NZ581958A (en) | 2004-11-12 | 2011-01-28 | Bayer Schering Pharma Ag | Recombinant newcastle disease virus comprising a transgene encoding a prodrug-converting enzyme or protease for use in the treatment of cancer |
| AU2006268780B2 (en) | 2005-07-08 | 2011-03-24 | University Of Zurich | Phage display using cotranslational translocation of fusion polypeptides |
| JP2010539915A (ja) | 2007-09-24 | 2010-12-24 | ユニバーシティ・オブ・チューリッヒ | 設計されたアルマジロリピートタンパク質 |
| CN101970490A (zh) | 2007-11-27 | 2011-02-09 | 埃博灵克斯股份有限公司 | 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽 |
| RU2550258C2 (ru) | 2008-11-03 | 2015-05-10 | Молекьюлар Партнерс Аг | Связывающие белки, ингибирующие взаимодействия vegf-a рецептора |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| US9221892B2 (en) | 2010-11-26 | 2015-12-29 | Molecular Partners Ag | Capping modules for designed ankyrin repeat proteins |
| EA201391607A1 (ru) | 2011-04-29 | 2014-04-30 | Янссен Байотек, Инк. | Связывающие il4/il13 белки с повторами и их применение |
| RU2014150224A (ru) | 2012-06-28 | 2016-08-20 | Молекьюлар Партнерс Аг | Сконструированный белок с анкириновым повтором, связывающийся с фактором роста тромбоцитов |
| JP2015532306A (ja) * | 2012-10-15 | 2015-11-09 | チューリッヒ大学 | 癌治療のための二重特異性ｈｅｒ２リガンド |
| EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| JP6486908B2 (ja) | 2013-05-31 | 2019-03-20 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 肝細胞増殖因子に結合する設計アンキリン反復タンパク質 |
| RU2769470C2 (ru) | 2015-04-02 | 2022-04-01 | Молекьюлар Партнерс Аг | Рекомбинантные связывающие белки и их применение |
-
2017
- 2017-09-20 CN CN201780058511.0A patent/CN109790206A/zh active Pending
- 2017-09-20 EP EP17778226.5A patent/EP3515933B9/en active Active
- 2017-09-20 JP JP2019536693A patent/JP6976335B2/ja not_active Expired - Fee Related
- 2017-09-20 BR BR112019005587A patent/BR112019005587A2/pt not_active Application Discontinuation
- 2017-09-20 ES ES17778226T patent/ES2953516T3/es active Active
- 2017-09-20 CA CA3036301A patent/CA3036301C/en active Active
- 2017-09-20 AR ARP170102593A patent/AR109680A1/es not_active Application Discontinuation
- 2017-09-20 MY MYPI2019001523A patent/MY196882A/en unknown
- 2017-09-20 NZ NZ751689A patent/NZ751689A/en not_active IP Right Cessation
- 2017-09-20 AU AU2017331329A patent/AU2017331329B2/en not_active Ceased
- 2017-09-20 US US15/710,001 patent/US10717772B2/en active Active
- 2017-09-20 PH PH1/2019/500596A patent/PH12019500596B1/en unknown
- 2017-09-20 MX MX2019003298A patent/MX377424B/es active IP Right Grant
- 2017-09-20 WO PCT/EP2017/073768 patent/WO2018054971A1/en not_active Ceased
- 2017-09-20 KR KR1020197009396A patent/KR102270315B1/ko not_active Expired - Fee Related
-
2019
- 2019-03-14 ZA ZA2019/01592A patent/ZA201901592B/en unknown
- 2019-03-19 IL IL265489A patent/IL265489B/en unknown
- 2019-03-20 SA SA519401369A patent/SA519401369B1/ar unknown
- 2019-03-21 CO CONC2019/0002609A patent/CO2019002609A2/es unknown
- 2019-03-21 CL CL2019000729A patent/CL2019000729A1/es unknown
-
2020
- 2020-06-22 US US16/907,415 patent/US20210130420A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PH12019500596A1 (en) | 2019-07-29 |
| SA519401369B1 (ar) | 2022-12-22 |
| NZ751689A (en) | 2021-07-30 |
| EP3515933B1 (en) | 2023-06-07 |
| CO2019002609A2 (es) | 2019-05-31 |
| CA3036301C (en) | 2021-04-20 |
| WO2018054971A1 (en) | 2018-03-29 |
| US10717772B2 (en) | 2020-07-21 |
| EP3515933A1 (en) | 2019-07-31 |
| MX2019003298A (es) | 2019-09-26 |
| ES2953516T3 (es) | 2023-11-14 |
| CA3036301A1 (en) | 2018-03-29 |
| RU2019111628A3 (es) | 2020-10-30 |
| IL265489B (en) | 2021-07-29 |
| RU2019111628A (ru) | 2020-10-19 |
| ZA201901592B (en) | 2021-04-28 |
| AR109680A1 (es) | 2019-01-09 |
| CN109790206A (zh) | 2019-05-21 |
| US20210130420A1 (en) | 2021-05-06 |
| JP2019531093A (ja) | 2019-10-31 |
| EP3515933B9 (en) | 2023-08-16 |
| AU2017331329A1 (en) | 2019-04-04 |
| US20180155402A1 (en) | 2018-06-07 |
| BR112019005587A2 (pt) | 2019-06-11 |
| KR102270315B1 (ko) | 2021-06-29 |
| AU2017331329B2 (en) | 2020-10-29 |
| EP3515933C0 (en) | 2023-06-07 |
| JP6976335B2 (ja) | 2021-12-08 |
| PH12019500596B1 (en) | 2024-02-21 |
| MY196882A (en) | 2023-05-08 |
| MX377424B (es) | 2025-03-10 |
| KR20190050802A (ko) | 2019-05-13 |
| IL265489A (en) | 2019-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019000729A1 (es) | Proteínas de unión recombinantes y sus usos. | |
| CL2020002043A1 (es) | Métodos y composiciones para la entrega de proteínas terapeuticas. | |
| CO2017009954A2 (es) | Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina | |
| CL2019000628A1 (es) | Anticuerpos anti-pd-1 y sus usos. | |
| MX2018003491A (es) | Represores de htt y usos de estos. | |
| DOP2019000165A (es) | Anticuerpos anti-ox40 y sus usos | |
| MX2019008359A (es) | Cadena j modificada. | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| AR111288A1 (es) | Anticuerpos anti-phf-tau y sus usos | |
| PE20170256A1 (es) | Proteinas de union y sus metodos de uso | |
| MX391249B (es) | Anticuerpos anti-muc16 y sus usos. | |
| BR112019000327A8 (pt) | Anticorpo para anticlaudina 18a2 e uso do mesmo | |
| MX2017010117A (es) | Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso. | |
| MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
| UY35964A (es) | Anticuerpos humanos para pd?1 | |
| CO2018012699A2 (es) | Anticuerpos anti-cd40 y sus usos | |
| MX2017008817A (es) | Composiciones y metodos para la glicosilacion de proteinas. | |
| MX2017012380A (es) | Derivados de maitansinoide, conjugados de los mismos, y metodos de uso. | |
| ECSP18096095A (es) | Anticuerpos a la alfa-sinucleína y usos de los mismos | |
| MX2019010040A (es) | Composiciones y métodos para el tratamiento del cáncer. | |
| AR109625A1 (es) | Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas | |
| CR20170240A (es) | Anticuerpos anti-interleucina-33 y sus usos | |
| MX2019004690A (es) | Constructos de anticuerpos. | |
| BR112018012262A2 (pt) | composições de interleucina-15 e seus usos | |
| DK3345613T3 (da) | Sammensætning til anvendelse i behandling af cancer eller en angiogeneserelateret sygdom omfattende et fusionsprotein af et tumorpenetrerende peptid og et anti-vegf-middel |